Equities

Read Gene SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RDG:WSE

Read Gene SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)5.62
  • Today's Change0.04 / 0.72%
  • Shares traded68.00
  • 1 Year change+21.65%
  • Beta0.0466
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Read Gene SA is a Poland-based company primarily engaged in the biotechnology sector. The Company is focused on research and technologies which aim is to detect, prevent and treat malignant tumors. The company's main segments are chemoprevention, clinical trials and genetic testing which are complementary to each other. Chemoprevention involves the use of natural or synthetic substances to inhibit, reverse or delay the process of cancer and in order to achieve that, the Company distributes supplements and food with products with a controlled content of micronutrients and vitamins. The Company provides clinical trials and offers them to corporate clients, mainly from the medical, pharmaceutical, chemical and biotechnology industries. The Company is also offering genetic testing services, including early lung cancer detection test, breast cancer test, colorectal cancer test or prostate cancer risk test.

  • Revenue in PLN (TTM)15.19m
  • Net income in PLN-887.46k
  • Incorporated2005
  • Employees11.00
  • Location
    Read Gene SAGrzepnica, ul. Alabastrowa 8SZCZECIN 72-003PolandPOL
  • Phone+48 914334256
  • Fax+48 918524433
  • Websitehttps://read-gene.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stem Cells Spin SA115.74k-510.92k18.19m1.00--2.7813.94157.15-0.0124-0.01240.00280.15810.01030.0083.43115,740.00-4.52-1.02-4.57-1.0595.9193.18-441.44-50.721.03-133.660.0262---87.06-37.78-237.07------
Medicofarma Biotech SA281.45k-3.06m33.99m24.00--7.14--120.76-0.0450-0.04500.00410.070.019966.640.746911,727.08-21.55-14.96-31.48-18.5938.8036.02-1,085.51-64.020.821-11.710.00--63.14-17.3933.11------
GENOMED SA27.49m3.27m41.22m53.0012.603.3110.231.502.482.4820.819.422.215.1712.68509,166.1026.317.5128.798.8165.2462.3311.903.847.51--0.00--2.343.1819.321.9815.97--
Sds Optic SA7.44m-483.71k48.51m41.00--49.40220.256.52-0.0815-0.08151.250.15590.54975.12125.84181,486.60-4.01-32.89-4.24-41.3598.1949.49-7.29-136.622.500.62780.00--40.53301.05-45.06--57.27--
Sygnis SA7.73m-6.34m57.60m12.00--1.79--7.45-0.2499-0.24990.33091.170.1166-0.16896.14218,427.70-9.03-8.61-15.00-12.10108.4959.85-77.44-39.140.6697-0.00660.13---52.2926.88-47.44---9.50--
Read Gene SA15.19m-887.46k66.26m11.00--24.73--4.36-0.0536-0.05361.170.22731.0839.776.30---6.32-2.40-6.88-2.7492.6390.21-5.84-4.306.31-0.6960.00--30.3826.3817.49------
Genomtec SA15.00k-11.01m75.17m----7.26--5,011.50-0.7485-0.74850.0010.68690.0009--0.0143---65.47-89.96-82.11-113.38-54,120.00-4,379.72-73,393.34-17,225.072.82-39.820.1409--0.00-63.42-24.35---34.54--
Urteste SA0.00-5.47m77.83m34.00--3.32-----3.88-3.880.0015.350.00-------15.56-29.65-18.99-31.35---45,933.33---623,333.30----0.0128------35.00--197.79--
Hyenergy SA3.29m169.85k77.91m27.00--3.95318.9023.69-0.0936-0.09360.16540.58780.18210.12590.7741--0.94032.391.283.3599.7077.465.163.111.301.170.00--192.8319.47100.30---45.79--
Nanogroup SA-6.90k-6.93m87.65m----7.51-----0.1844-0.1844-0.00020.3553-0.00032.64-----30.59-29.50-51.55-33.80--66.72---2,258.260.9785-464.180.00--3.96-64.0934.50--3.07--
Poltreg SA0.00-24.56m127.31m33.00--2.57-----5.27-5.270.0010.610.0016.45--0.00-25.87-9.02-29.62-10.18---659.36---854.232.65--0.1365---74.98-6.89-38.06--83.47--
Mabion SA14.81m-59.30m132.53m204.00--1.89--8.95-3.67-3.670.91644.330.09888.1027.2572,602.94-39.560.5366-54.811.06-178.5558.34-400.370.96430.2276--0.04---54.50---115.35--6.00--
Molecure SA5.11m-24.42m151.85m71.00--1.70--29.70-1.20-1.200.24934.340.0553--7.0150,119.41-26.42-3.15-27.53-3.3051.4893.34-477.67-15.45----0.0588---40.47278.20-10.27--12.49--
Data as of Feb 13 2026. Currency figures normalised to Read Gene SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.